Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months. 

Industry leaders including Sanofi's ex-CEO and the chiefs of Sun, Lupin, Glenmark, Dr Reddy’s and Cipla discuss how India could leapfrog its pharma R&D efforts. Could the South Korea model or a hybrid approach including bringing back top talent bolster the country’s efforts to emerge as a global innovation hot spot?

Industry leaders and experts, including executives from McKinsey, Eight Roads Ventures and Novartis, share global best practices, insights and expectations around how India could accelerate its journey towards becoming a biopharma innovation hub.

A top virologist and prominent Chinese researcher sounds alarm over reluctance to clear mRNA vaccines amid regional outbreaks and the government rollout of inactivated virus-based booster shots without real-word evidence.

In this video fireside chat from the recent BIO-Europe Digital 2021 conference, the CEO of Institut Pasteur Korea outlines the research institute's role in managing the COVID-19 situation in the country, progress with the COVID-19 pipeline, issues related to the development of drugs and vaccines for the pandemic in South Korea, and her goals for the institute over the next few years.

China has signaled that it will offer a more level playing field to foreign players as part of a bid to join a major regional trade pact but some see the gesture as offering little real relief and high hurdles remain.

The firm’s sole nephrological asset has demonstrated proof of concept, helping advance the novel gene-targeted therapy into pivotal development early next year.

The company’s lead candidate, AP1189, has shown promise in a mid-stage rheumatoid arthritis study, sparking plans for an imminent strategic business collaboration. 

We clean out your Thanksgiving and Black Friday inbox so you don’t have to. Stories you may have missed over the holidays.

Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.

The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.

The Irish firm needs to give regulators in the US more information on its epidermolysis bullosa therapy but is confident of address those requests from its "existing data within the time periods required," according to CEO Joe Wiley.